×
For best experience we recommend to activate Javascript in your browser.
MAP3K15 antibody (N-Term)
This anti-MAP3K15 antibody is a Rabbit Polyclonal antibody detecting MAP3K15 in WB, ELISA, FACS and IHC. Suitable for Human.
Quick Overview for MAP3K15 antibody (N-Term) (ABIN2306964)
Target
See all MAP3K15 Antibodies
MAP3K15
(Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15))
Reactivity
All reactivities for MAP3K15 antibodies
Human
Host
All hosts for MAP3K15 antibodies
Rabbit
Clonality
All clonalities for MAP3K15 antibodies
Polyclonal
Conjugate
All conjugates for MAP3K15 antibodies
This MAP3K15 antibody is un-conjugated
Application
All applications for MAP3K15 antibodies
Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunohistochemistry (IHC)
Product Details anti-MAP3K15 Antibody
(hide)
Binding Specificity
All epitopes for MAP3K15 antibodies
AA 314-342, N-Term
Cross-Reactivity
Human, Mouse (Murine)
Cross-Reactivity (Details)
Calculated cross reactivity: Hu Mo
Characteristics
MAP3K15, NT (MAP3K15, ASK3, Mitogen-activated protein kinase kinase kinase 15, Apoptosis signal-regulating kinase 3, MAPK/ERK kinase kinase 15)
Purification
Purified by Protein A affinity chromatography.
Immunogen
MAP3K15 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 314-342 amino acids from the N-terminal region of human MAP3K15.
Isotype
IgG
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working conditions should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Buffer
Supplied as a liquid in PBS, pH 7.2, 0.09 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
-20°C
Target Details for MAP3K15
(hide)
Target
MAP3K15
(Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15))
Alternative Name
MAP3K15
NCBI Accession
NP_001001671
UniProt
Q6ZN16
Recently viewed
(hide)
Chat with us , powered by LiveChat